| Filed On | Filing |
|---|---|
| 13 Nov 2026 |
8-K: Results of Operations and Financial Condition
Name changed from Quince Therapeutics, Inc. to IRulya Therapeutics Inc.; common stock began trading on the Nasdaq Capital Market under the ticker “IRLA” on October 12, 2026 |
| 19 Oct 2026 |
8-K: Regulation FD Disclosure
DISCLAIMERS The information in this Presentation has been prepared by IRulya Therapeutics Inc. (formerly Quince Therapeutics, Inc., “IRulya”, and the “company”) and contains information pertaining to the business and operations of the co... |
| 09 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year +2 more
This Executive Change in Control and Severance Agreement (the “Agreement”) is made and entered into by and between John Militello (“Executive”) and Quince Therapeutics, Inc. (the “Company”), effective as of September 16, 2026 (the “Effec... |
| 06 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more
(a) Successor to Prior Plans. The Plan is the successor to the Prior Plans. As of the Effective Date, (i) no additional awards may be granted under the Prior Plans; and (ii) all outstanding awards granted under a Prior Plan will remain s... |
| 02 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On September 30, 2026, each of June Bray, David Lamond and Christopher Senner (collectively, the “Resigning Directors”) tendered conditional resignations from the Board of Directors (the “Board”) of Quince Therapeutics, Inc. (the “Compan... |
| 14 Sep 2026 |
8-K: Completion of Acquisition or Disposition of Assets; Departure/Election of Directors or Officers; Compensation
Quince Therapeutics, Inc., a Delaware corporation (the "Company” or "Seller"), Quince Therapeutics SpA, a company organized under the laws of Italy ("Quince SPA", "Italian Subsidiary") entered into an asset purchase agreement (the "APA")... |
| 04 Sep 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
On August 31, 2026, Quince Therapeutics, Inc. (the “Company”) received a written notification (“Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based on the Compan... |
| 27 Aug 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On August 23, 2026, Quince Therapeutics, Inc. (the “Company”) and Charles Ryan, the Company’s President, determined that Mr. Ryan’s last day of employment will be September 8, 2026. In connection with the conclusion of his service as the... |
| 17 Aug 2026 |
8-K: Other Events
On May 18, 2026, Quince Therapeutics, Inc., a Delaware corporation (the “Company” or “Quince”), acquired Orphai Therapeutics, LLC (formerly Orphai Therapeutics, Inc., “Orphai”), a Delaware limited liability company and wholly owned subsi... |
| 14 Aug 2026 |
8-K: Results of Operations and Financial Condition
Completed acquisition of Orphai Therapeutics, adding LAM-001, an inhaled formulation of rapamycin for the treatment of multiple serious, underserved pulmonary diseases, to pipeline |
| 31 Jul 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On July 29, 2026, each of Dirk Thye, the Chief Executive Officer and Chief Medical Officer of Quince Therapeutics, Inc. (the “Company”), and a member of the Company’s board of directors (the “Board”), and Brendan Hannah, the Company’s Ch... |
| 26 Jun 2026 |
8-K: Material Modification to Rights of Security Holders; Amendments to Articles/Bylaws; Change in Fiscal Year
Quince Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), does hereby certify as follows: |
| 11 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
The Annual Meeting of Stockholders of Quince Therapeutics, Inc. (the “Company”) was held online via live webcast on June 11, 2026 (the “Annual Meeting”). At the Annual Meeting, there were present, in person virtually or by proxy, holders... |
| 21 May 2026 |
8-K: Other Events
As previously disclosed, on March 17, 2026, Quince Therapeutics, Inc. (the “Company”) received a notice from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company had failed... |
| 18 May 2026 |
8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +4 more
Form of Certificate of Designation of Series C Convertible Preferred Stock |
| 28 Apr 2026 |
8-K: Other Events
On April 27, 2026, Quince Therapeutics, Inc. (the “Company”), received a letter from the Nadsaq Listing Qualifications department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it has regained complian... |
| 22 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 09 Apr 2026 |
8-K: Material Modification to Rights of Security Holders; Amendments to Articles/Bylaws; Change in Fiscal Year
Quince Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), does hereby certify as follows: |
| 30 Mar 2026 |
8-K: Termination of a Material Definitive Agreement; Regulation FD Disclosure
SOUTH SAN FRANCISCO, Calif. – March 30, 2026 – Quince Therapeutics, Inc. (Nasdaq: QNCX) today announced the successful settlement of the company’s outstanding obligations under its loan from the European Investment Bank (EIB) for a payme... |
| 20 Mar 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
On March 16, 2026, Quince Therapeutics, Inc. (the “Company”) received a notice (the “Bid Price Notice”) from the Nasdaq Listing Qualifications department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) stating that the closing bi... |
Loading...